Ischemic preconditioning reduces infarct size in patients treated with primary angioplasty

Original title: Preinfarction Angina Reduces Infarct Size in ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention Reference: Ronald Reiter et al. Circ Cardiovasc Interv. 2013;6:00-00.

Ischemic preconditioning (IPC) is a phenomenon whereby transitory ischemia episodes protect the myocardium against a more prolonged episode. 

Until now, IPC has been the most effective approach to protect the myocardium. Pre infarction angina is a clinical surrogate of IPC and has been associated with reduced infarct size in patients that receive thrombolytic therapy; however this is not conclusive for patients treated with primary angioplasty.

245 patients with ST elevation myocardial infarction treated with primary angioplasty were analyzed; 79 of these patients had presented angina 24 hours before admition vs. 166 patients without pre infarction angina. There were no significant differences in the rest of baseline characteristics between both groups.

For the patients with previous angina, both infarct size and troponin peak was significantly reduced (p<0,0001) despite having identical ischemic times and angiographic results. Ejection Fraction was 4$ lower in patients with preconditioning (51,4±1,1% vs. 47,5±1%; p=0,02).

Conclusion 

This study is the most detailed analysis carried out so far on the potential protective effect of ischemic preconditioning in patients with ST elevation myocardial infarction treated with primary angioplasty.

Editorial Comment

Randomized studies on ST elevation acute coronary syndromes should start considering pre infarction angina among key variables, seeing that this could be an important confounder, mainly if infarct size is one of the primary concerns. A good example of this is the large number of trials assessing the use of thrombi aspiration.

SOLACI.ORG

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...